Latest Kallikrein Stories
SOUTHAMPTON, England, August 20, 2014 /PRNewswire/ -- Phase I Trial of Plasma Kallikrein Inhibitor to be Conducted in the US KalVista Pharmaceuticals ("KalVista"),
SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents.
A harmless digestive enzyme evolved twice into a dangerous toxin in 2 unrelated species.
NANTONG CITY, China, Oct. 8 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc.
It has been known for a long time that T cells can attack the body's own structures and, if they infiltrate the CNS, cause diseases such as multiple sclerosis